The First Affiliated Hospital of University of Science and Technology | China
Dr. Runze Wen is an emerging scholar in the field of Cardiac Nuclear Medicine, currently pursuing his doctoral degree at the University of Science and Technology of China. His research focuses on advancing nuclear imaging techniques for cardiovascular diagnostics, with a strong emphasis on enhancing the precision and clinical applicability of cardiac assessments. Despite being at an early stage in his academic career, Dr. Wen has already demonstrated remarkable productivity and impact within the scientific community, with 3 published documents, 13 citations across 13 referencing works, and an h index of 3, a clear indication of the relevance and influence of his research. His investigations often integrate nuclear imaging modalities with innovative diagnostic approaches to improve the understanding of coronary microvascular dysfunction and other complex cardiac conditions. In addition to his academic achievements, Dr. Wen is a Fellow in Training (FIT) member of the American College of Cardiology (ACC), reflecting his commitment to professional development and international collaboration within the cardiology field. His ability to bridge advanced imaging science with clinical cardiology has earned him recognition as a promising young researcher dedicated to transforming cardiovascular diagnostics. Through his ongoing research and active engagement in academic circles, Dr. Runze Wen continues to contribute meaningfully to the future of nuclear cardiology, aiming to enhance patient care through evidence based innovation and interdisciplinary research excellence.
Profiles: Scopus | Orcid
Featured Publications
Wen, R., Xie, Q., Pan, B., Ni, M., Zhu, X., Meng, X., Wei, Z., Wu, X., Li, D., & Wang, X. (2025). Simultaneous 13N-ammonia and gadolinium perfusion using integrated PET–MRI: Diagnostic accuracy in coronary microvascular dysfunction. Frontiers in Medicine
Wen, R., Zhao, M., Chen, C., Yang, Y., & Zhang, B. (2023). A novel nomogram integrated with preablation stimulated thyroglobulin and thyroglobulin/thyroid-stimulating hormone ratio to predict the therapeutic response of intermediate- and high-risk differentiated thyroid cancer patients: A bi-center retrospective study.